Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 13.05
CRDC's Cash to Debt is ranked higher than
83% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. CRDC: 13.05 )
CRDC' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 13.05

Equity to Asset 0.83
CRDC's Equity to Asset is ranked higher than
89% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. CRDC: 0.83 )
CRDC' s 10-Year Equity to Asset Range
Min: -5.64   Max: 0.86
Current: 0.83

-5.64
0.86
F-Score: 4
Z-Score: -1.51
M-Score: 2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -460.01
CRDC's Operating margin (%) is ranked lower than
55% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. CRDC: -460.01 )
CRDC' s 10-Year Operating margin (%) Range
Min: -1065.07   Max: -26.6
Current: -460.01

-1065.07
-26.6
Net-margin (%) -471.69
CRDC's Net-margin (%) is ranked lower than
54% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.99 vs. CRDC: -471.69 )
CRDC' s 10-Year Net-margin (%) Range
Min: -1281.1   Max: -26.56
Current: -471.69

-1281.1
-26.56
ROE (%) -105.24
CRDC's ROE (%) is ranked lower than
51% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. CRDC: -105.24 )
CRDC' s 10-Year ROE (%) Range
Min: -171.5   Max: -45.86
Current: -105.24

-171.5
-45.86
ROA (%) -74.15
CRDC's ROA (%) is ranked lower than
53% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. CRDC: -74.15 )
CRDC' s 10-Year ROA (%) Range
Min: -108.53   Max: -33.08
Current: -74.15

-108.53
-33.08
ROC (Joel Greenblatt) (%) -711.68
CRDC's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. CRDC: -711.68 )
CRDC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1119.89   Max: -343.27
Current: -711.68

-1119.89
-343.27
Revenue Growth (%) -51.30
CRDC's Revenue Growth (%) is ranked lower than
52% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. CRDC: -51.30 )
CRDC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 13.6
Current: -51.3

0
13.6
EBITDA Growth (%) 33.20
CRDC's EBITDA Growth (%) is ranked higher than
95% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. CRDC: 33.20 )
CRDC' s 10-Year EBITDA Growth (%) Range
Min: -54.9   Max: 33.2
Current: 33.2

-54.9
33.2
EPS Growth (%) 31.70
CRDC's EPS Growth (%) is ranked higher than
90% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. CRDC: 31.70 )
CRDC' s 10-Year EPS Growth (%) Range
Min: -51.5   Max: 31.7
Current: 31.7

-51.5
31.7
» CRDC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CRDC Guru Trades in Q4 2013

PRIMECAP Management 2,599,600 sh (unchged)
Jim Simons 49,500 sh (-39.03%)
» More
Q1 2014

CRDC Guru Trades in Q1 2014

Chuck Royce 169,600 sh (New)
PRIMECAP Management 2,599,600 sh (unchged)
Jim Simons 15,700 sh (-68.28%)
» More
Q2 2014

CRDC Guru Trades in Q2 2014

PRIMECAP Management 5,842,700 sh (+124.75%)
Jim Simons Sold Out
Chuck Royce 114,486 sh (-32.5%)
» More
Q3 2014

CRDC Guru Trades in Q3 2014

PRIMECAP Management 5,864,500 sh (+0.37%)
Chuck Royce 54,486 sh (-52.41%)
» More
» Details

Insider Trades

Latest Guru Trades with CRDC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 Add 124.75%$0.85 - $1.29 $ 0.65-36%5842700
PRIMECAP Management 2013-03-31 Add 120.41%$1.1 - $1.68 $ 0.65-53%2599300
PRIMECAP Management 2012-06-30 Add 50.94%$1.69 - $2.2 $ 0.65-66%1031600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.30
CRDC's P/B is ranked higher than
72% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. CRDC: 3.30 )
CRDC' s 10-Year P/B Range
Min: 1.26   Max: 15.73
Current: 3.3

1.26
15.73
P/S 11.00
CRDC's P/S is ranked higher than
52% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. CRDC: 11.00 )
CRDC' s 10-Year P/S Range
Min: 1.54   Max: 35.68
Current: 11

1.54
35.68
EV-to-EBIT -2.33
CRDC's EV-to-EBIT is ranked higher than
56% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.42 vs. CRDC: -2.33 )
CRDC' s 10-Year EV-to-EBIT Range
Min: -37.2   Max: -0.4
Current: -2.33

-37.2
-0.4
Current Ratio 14.17
CRDC's Current Ratio is ranked higher than
98% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. CRDC: 14.17 )
CRDC' s 10-Year Current Ratio Range
Min: 1.7   Max: 21.42
Current: 14.17

1.7
21.42
Quick Ratio 13.70
CRDC's Quick Ratio is ranked higher than
99% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. CRDC: 13.70 )
CRDC' s 10-Year Quick Ratio Range
Min: 1.26   Max: 20.95
Current: 13.7

1.26
20.95

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.10
CRDC's Price/Net Cash is ranked higher than
98% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. CRDC: 2.10 )
CRDC' s 10-Year Price/Net Cash Range
Min: 2.52   Max: 107.5
Current: 2.1

2.52
107.5
Price/Net Current Asset Value 5.25
CRDC's Price/Net Current Asset Value is ranked higher than
92% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. CRDC: 5.25 )
CRDC' s 10-Year Price/Net Current Asset Value Range
Min: 2.22   Max: 110
Current: 5.25

2.22
110
Price/Tangible Book 3.15
CRDC's Price/Tangible Book is ranked higher than
80% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.44 vs. CRDC: 3.15 )
CRDC' s 10-Year Price/Tangible Book Range
Min: 1.68   Max: 14.33
Current: 3.15

1.68
14.33
Price/Median PS Value 0.76
CRDC's Price/Median PS Value is ranked higher than
92% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. CRDC: 0.76 )
CRDC' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.92
Current: 0.76

0.16
1.92
Earnings Yield (Greenblatt) -40.90
CRDC's Earnings Yield (Greenblatt) is ranked lower than
54% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. CRDC: -40.90 )
CRDC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -40.9

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 4 8 17
EPS($) -0.22 -0.21 -0.16
EPS without NRI($) -0.22 -0.21 -0.16

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:C5V.Germany,
Cardica, Inc. was incorporated in Delaware in October 1997 as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Its business is focused on the design, manufacture and marketing of proprietary automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery. It has re-focused its business on the development of an endoscopic microcutter product line intended for use by thoracic, bariatric, colorectal and general surgeons. The first product that it is developing in its planned microcutter product line is the Microcutter XPRESS 30, the first true multi-fire endolinear microcutter device based on its proprietary 'staple-on-a-strip' technology, which would expand its commercial opportunity into additional surgical markets. In addition, it is developing the Microcutter XPRESS 45, a planned multi-fire endolinear microcutter device with a 45 millimeter staple line, the Microcutter XCHANGE 30, a planned cartridge based microcutter device with a 5 millimeter shaft diameter and a 30 millimeter staple line, the Microcutter FLEXCHANGE 30, a planned cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling, and the Microcutter XPRESS 60, a planned cutting and stapling device designed for the bariatric and thoracic surgery markets. The Company's C-Port Distal Anastomosis Systems, or C-Port systems, are sold in the United States and Europe. The C-Port systems are used to perform a distal anastomosis, which is the connection between a bypass graft vessel and the target coronary artery. It intends to launch a full range of surgical stapling devices that cover the needs of thoracic, bariatric, colorectal and general surgeons. It designs, manufactures and markets proprietary automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump CABG procedures. It currently markets four proprietary products to perform anastomoses, the C-Port xA system, the C-Port Flex A system, the C-Port X-CHANGE system and the PAS-Port system. The FDA and other regulatory bodies extensively regulate the research, development, manufacture, labeling, distribution and marketing of its products.
» More Articles for CRDC

Headlines

Articles On GuruFocus.com
comment on CRDC Mar 23 2013 
CARDICA, INC. Reports Operating Results (10-Q) Feb 11 2011 
CARDICA, INC. Reports Operating Results (10-Q) Nov 15 2010 
CARDICA, INC. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buy Highlight: CARDICA, NewBridge Bancorp, WESCO International, PrivateBancorp Inc., Syno Nov 07 2009 
CARDICA, INC. Reports Operating Results (10-Q) Nov 06 2009 
CARDICA, INC. (CRDC) CFO Robert Y Iv Newell buys 16,000 Shares Nov 04 2009 
Weekly CFO Buy Highlights: Cardica, Inc. (CRDC), American International Industries Inc (AMIN) Oct 10 2009 
CARDICA, INC. (CRDC) CEO Bernard A Hausen buys 19,960 Shares Oct 02 2009 
CARDICA, INC. (CRDC) CFO Robert Y Iv Newell buys 11,976 Shares Oct 02 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Dec 16 2014
CARDICA INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Dec 12 2014
Broadfin Capital Thanks Shareholders For Their Overwhelming Support In Electing Its Three Director... Dec 12 2014
Strength Seen in Cardica (CRDC): Stock Moves 8.7% Higher Dec 04 2014
Cardica Issues Statement Regarding 2014 Annual Meeting of Stockholders Nov 24 2014
Cardica Issues Statement Regarding 2014 Annual Meeting of Stockholders Nov 24 2014
Cardica (CRDC) in Focus: Stock Moves Up 8.7% in Session Nov 24 2014
CARDICA INC Financials Nov 21 2014
Broadfin Capital Gratified To Have All Three Of Its Nominees Certain To Join The Board Of Directors... Nov 21 2014
Cardica (CRDC) in Focus: Stock Tumbles 9.1% Nov 21 2014
CARDICA INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 20 2014
Cardica Releases Letter To Stockholders Nov 20 2014
Cardica Releases Letter To Stockholders Nov 20 2014
Cardica Announces Shift In Focus Nov 18 2014
10-Q for Cardica, Inc. Nov 14 2014
Broadfin Issues Open Letter To Cardica's Shareholders Nov 13 2014
CARDICA INC Files SEC form 10-Q, Quarterly Report Nov 12 2014
Cardica Files Definitive Proxy Materials and Mails Letter to Stockholders Nov 10 2014
Cardica Files Definitive Proxy Materials and Mails Letter to Stockholders Nov 10 2014
Cardica Announces Fiscal 2015 First Quarter Financial Results Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK